MX2019007433A - Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados. - Google Patents

Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.

Info

Publication number
MX2019007433A
MX2019007433A MX2019007433A MX2019007433A MX2019007433A MX 2019007433 A MX2019007433 A MX 2019007433A MX 2019007433 A MX2019007433 A MX 2019007433A MX 2019007433 A MX2019007433 A MX 2019007433A MX 2019007433 A MX2019007433 A MX 2019007433A
Authority
MX
Mexico
Prior art keywords
methods
formulations
reconstitution time
reducing
lyophilized polypeptides
Prior art date
Application number
MX2019007433A
Other languages
English (en)
Inventor
Michael Heynes Christopher
Edward Luoma Jacob
John Lim Fredric
Angelo Eleazar Zarraga Isidro
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2019007433A publication Critical patent/MX2019007433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a métodos y formulaciones útiles para reducir el tiempo de reconstitución de polipéptidos liofilizados.
MX2019007433A 2016-12-22 2017-12-21 Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados. MX2019007433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662438232P 2016-12-22 2016-12-22
PCT/US2017/068024 WO2018119312A1 (en) 2016-12-22 2017-12-21 Methods and formulations for reducing reconstitution time of lyophilized polypeptides

Publications (1)

Publication Number Publication Date
MX2019007433A true MX2019007433A (es) 2019-08-16

Family

ID=61028185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007433A MX2019007433A (es) 2016-12-22 2017-12-21 Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.

Country Status (13)

Country Link
US (2) US11377505B2 (es)
EP (1) EP3558366A1 (es)
JP (2) JP2020503316A (es)
KR (1) KR102579836B1 (es)
CN (1) CN110049778A (es)
AR (1) AR110431A1 (es)
AU (1) AU2017382281A1 (es)
BR (1) BR112019012686A2 (es)
CA (1) CA3044686A1 (es)
IL (1) IL267439B2 (es)
MX (1) MX2019007433A (es)
TW (1) TWI783958B (es)
WO (1) WO2018119312A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021217370A1 (en) 2020-02-04 2022-08-18 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product
WO2023212559A1 (en) * 2022-04-26 2023-11-02 Amgen Inc. Lyophilization method

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE122006000006I2 (de) 1991-08-14 2011-06-16 Genentech Inc Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
EP0656789B1 (en) 1992-08-21 1997-12-17 Genentech, Inc. Method for treating a lfa-1-mediated disorder
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US5677426A (en) 1994-03-03 1997-10-14 Genentech, Inc. Anti-IL-8 antibody fragments
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1297847A3 (en) 1996-01-23 2003-05-07 Genentech, Inc. Anti-CD18 antibodies in stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DK1516629T3 (da) 1996-11-27 2013-06-03 Genentech Inc Humaniseret anti-CD-11a antibodies
CA2287911C (en) 1997-05-15 2014-05-06 Genentech, Inc. Apo-2 receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60039448D1 (de) 1999-10-29 2008-08-21 Genentech Inc Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2004070011A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
CA2681341A1 (en) 2007-03-22 2008-09-25 Genentech, Inc. Apoptotic anti-ige antibodies
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
EA029972B1 (ru) * 2011-02-09 2018-06-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы получения полипептидных композиций
MA38176A1 (fr) 2012-11-13 2017-06-30 Genentech Inc Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
SG11201605862WA (en) * 2014-01-20 2016-08-30 Eveon Process for reconstitution of a solid form of a pharmaceutical composition
CN104689297A (zh) * 2015-03-20 2015-06-10 陈卓杰 醋酸奥曲肽冻干粉针制剂及其制备方法

Also Published As

Publication number Publication date
BR112019012686A2 (pt) 2019-11-19
AU2017382281A1 (en) 2019-06-13
US20220298263A1 (en) 2022-09-22
US20190389974A1 (en) 2019-12-26
EP3558366A1 (en) 2019-10-30
TWI783958B (zh) 2022-11-21
IL267439B2 (en) 2023-02-01
WO2018119312A8 (en) 2019-07-11
JP2023012465A (ja) 2023-01-25
AR110431A1 (es) 2019-03-27
JP2020503316A (ja) 2020-01-30
KR20190099212A (ko) 2019-08-26
IL267439B (en) 2022-10-01
WO2018119312A1 (en) 2018-06-28
TW201827078A (zh) 2018-08-01
KR102579836B1 (ko) 2023-09-15
CA3044686A1 (en) 2018-06-28
US11377505B2 (en) 2022-07-05
CN110049778A (zh) 2019-07-23
IL267439A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MY191581A (en) Anti-pd-1 antibodies
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
TW201613966A (en) SynTac polypeptides and uses thereof
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
SG10201809457YA (en) Insulin receptor partial agonists
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2020004419A (es) Polipeptidos fhbp meningococicos modificados.
MY191539A (en) Streptococcal vaccine
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2020012893A (es) Formulaciones de proteinas.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12017502277A1 (en) Multi-specific binding proteins
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019007433A (es) Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
EP3319930A4 (en) METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
NZ721832A (en) Solid forms of tenofovir